GCM
PLRX icon

Graham Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Graham Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-333,421
Closed -$450K – 1544
2025
Q1 		$450K Buy
+333,421
New +$2.02M 0.01% 855
2024
Q4 		– Sell
-13,986
Closed -$157K – 1428
2024
Q3 		$157K Sell
13,986
-1,036
-7% -$13K ﹤0.01% 965
2024
Q2 		$161K Buy
+15,022
New +$194K ﹤0.01% 889
2022
Q3 		– Sell
-10,202
Closed -$81K – 1259
2022
Q2 		$81K Buy
+10,202
New +$65.3K ﹤0.01% 967

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Graham Capital Management's PLRX Position: Q2 2025 in Review

Graham Capital Management sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 333,421 shares — an estimated $450K sold.

Graham Capital Management first reported a position in PLRX in Q2 2022 and held it in 4 quarters. The position peaked at $450K in Q1 2025. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • Graham Capital Management reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 333,421 Pliant Therapeutics shares in Q2 2025, an estimated $450K.
  • Graham Capital Management first reported a position in Pliant Therapeutics in Q2 2022 and held it in 4 quarters.
  • Graham Capital Management's Pliant Therapeutics position peaked at $450K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.